Barbaro Giuseppe, Klatt Edward C
Department of Medical Pathophysiology, University La Sapienza, Rome, Italy.
Curr Pharm Des. 2003;9(18):1475-81. doi: 10.2174/1381612033454711.
Highly active antiretroviral therapy (HAART) has prolonged many patients' lives, but many cardiac sequelae of HIV are not affected by HAART and continue to develop even with treatment. In addition, HAART itself causes in a high proportion of patients a metabolic syndrome, characterized by lipodystrophy/ lipoatrophy, dyslipidemia and insulin resistance that may be associated with an increase in peripheral artery and coronary artery diseases. Careful cardiovascular evaluation in the course of HIV disease can identify cardiac complications early enough to treat. All HIV-infected patients who are either candidates to antiretroviral therapy or who are already under treatment should undergo an assessment that includes the evaluation of the cardiovascular risk with the available guidelines and the interactions between antiretrovirals and drugs commonly used to treat cardiovascular disease.
高效抗逆转录病毒疗法（HAART）延长了许多患者的生命，但HIV的许多心脏后遗症不受HAART影响，即使接受治疗仍会继续发展。此外，HAART本身在很大一部分患者中会引发代谢综合征，其特征为脂肪代谢障碍/脂肪萎缩、血脂异常和胰岛素抵抗，这些可能与外周动脉疾病和冠状动脉疾病的增加有关。在HIV疾病过程中进行仔细的心血管评估能够尽早识别心脏并发症以便进行治疗。所有抗逆转录病毒治疗候选者或已接受治疗的HIV感染患者均应接受评估，包括根据现有指南评估心血管风险以及抗逆转录病毒药物与常用心血管疾病治疗药物之间的相互作用。
